Acadia (ACAD) +6.4% after saying that its Pimavanserin performed well in a Phase III trial,...
Acadia (ACAD) +6.4% after saying that its Pimavanserin performed well in a Phase III trial, showing a "robust and consistent efficacy...across a wide array of study measures" and confirming previous "positive top-line results." Twice as many patients treated with pimavanserin were rated as "very much improved or much improved" vs those given a placebo. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Feb 25, 2015)
at Nasdaq.com (Feb 3, 2015)
at Nasdaq.com (Jan 23, 2015)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Dec 12, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs